テルミサルタン市場レポート：適応症別、流通チャネル別、地域別、2024～2032年

世界のテルミサルタン市場規模は2023年に37億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて2.7%の成長率（CAGR）を示し、2032年には48億米ドルに達すると予測しています。

テルミサルタンは非ペプチド性のアンジオテンシン受容体拮抗薬（ARB）で、高血圧や心血管障害の治療に処方薬として使用されます。テルミサルタンは錠剤と経口油懸濁液の2種類があり、効果を高めるために他の薬剤と併用されます。降圧作用を示し、体内のアルドステロン産生を阻害することにより、ナトリウムと水分の吸収を減少させ、血圧を低下させる。また、テルミサルタンは血管を弛緩させ、腎機能を促進します。しかし、めまい、ふらつき、咳、副鼻腔痛など様々な副作用を引き起こす可能性があります。

テルミサルタン市場動向

世界の製薬業界の著しい成長は、市場の明るい展望を生み出す重要な要因のひとつです。さらに、高血圧、糖尿病、さまざまな腎臓関連疾患の有病率の増加が、市場の成長を後押ししています。テルミサルタンは、インスリン感作の遺伝子を改変し、グルコースと脂質の代謝を調節する効果が証明されており、慢性糖尿病性腎疾患や、座りがちな生活習慣によって引き起こされるその他の疾患の管理に役立っています。製薬メーカーはまた、高血圧や心血管疾患に対する費用対効果の高い治療を提供するため、テルミサルタン薬のジェネリック・バージョンを発売しています。さらに、製薬メーカーは糖尿病性腎症の治療のための先進的なテルミサルタン薬の研究開発（R&D）に多額の投資を行っており、これも市場の成長に寄与しています。その他、高齢者人口の増加や医療インフラの大幅な改善などが、市場をさらに牽引すると予想されます。

本レポートで扱う主要質問

• 世界のテルミサルタン市場はこれまでどのように推移し、今後どのように推移していくのか？
• COVID-19は世界のテルミサルタン市場にどのような影響を与えたか？
• 主要地域市場とは？
• 適応症別の市場内訳は？
• 流通チャネル別の市場内訳は？
• 業界のバリューチェーンにおける様々なステージとは？
• 業界の主要な促進要因と課題は何か？
• 世界のテルミサルタン市場の構造と主要参入企業は？
• 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のテルミサルタン市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：適応症別

• 高血圧
• 心血管リスクの軽減

第7章 市場内訳：流通チャネル別

• 病院薬局
• ドラッグストアと薬局
• オンラインストア

第8章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第9章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第12章 価格分析

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • Aurobindo Pharma USA
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Hikma Pharmaceuticals plc
  • Jubilant Cadista Pharmaceutical
  • Sanofi S.A.
  • Solco Healthcare（Prinston Pharmaceutical Inc.）
  • Torrent Pharmaceuticals Ltd

List of Figures

• Figure 1: Global: Telmisartan Market: Major Drivers and Challenges
• Figure 2: Global: Telmisartan Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Telmisartan Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Telmisartan Market: Breakup by Indication (in %), 2023
• Figure 5: Global: Telmisartan Market: Breakup by Distribution Channel (in %), 2023
• Figure 6: Global: Telmisartan Market: Breakup by Region (in %), 2023
• Figure 7: Global: Telmisartan (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Telmisartan (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Telmisartan (Cardiovascular Risk Reduction) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Telmisartan (Cardiovascular Risk Reduction) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Telmisartan (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Telmisartan (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Telmisartan (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Telmisartan (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: North America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: North America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: United States: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: United States: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Canada: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Canada: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Asia-Pacific: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Asia-Pacific: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: China: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: China: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Japan: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Japan: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: India: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: India: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: South Korea: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: South Korea: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Australia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Australia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Indonesia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: Indonesia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: Europe: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: Europe: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: Germany: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: Germany: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: France: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: France: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: United Kingdom: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: United Kingdom: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: Italy: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: Italy: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: Spain: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: Spain: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: Russia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: Russia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: Latin America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: Latin America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: Brazil: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: Brazil: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Mexico: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Mexico: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Middle East and Africa: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Middle East and Africa: Telmisartan Market: Breakup by Country (in %), 2023
• Figure 65: Middle East and Africa: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Global: Telmisartan Industry: SWOT Analysis
• Figure 67: Global: Telmisartan Industry: Value Chain Analysis
• Figure 68: Global: Telmisartan Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Telmisartan Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Telmisartan Market Forecast: Breakup by Indication (in Million US$), 2024-2032
• Table 3: Global: Telmisartan Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 4: Global: Telmisartan Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Telmisartan Market: Competitive Structure
• Table 6: Global: Telmisartan Market: Key Players

The global telmisartan market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032.

Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.

Telmisartan Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and distribution channel.

Breakup by Indication:

Hypertension

Cardiovascular Risk Reduction

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.

Key Questions Answered in This Report:

• How has the global telmisartan market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global telmisartan market?
• What are the key regional markets?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global telmisartan market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Telmisartan Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Hypertension
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Cardiovascular Risk Reduction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Drug Stores and Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Stores
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Aurobindo Pharma USA
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 Boehringer Ingelheim International GmbH
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Cipla Limited
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Hikma Pharmaceuticals plc
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Jubilant Cadista Pharmaceutical
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 Sanofi S.A.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Torrent Pharmaceuticals Ltd
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis